Product
nal-irinotecan (nal-iri)
1 clinical trial
4 indications
Indication
Pancreatic CancerIndication
MetastasisIndication
SurgeryIndication
Oligometastatic DiseaseClinical trial
Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the PancreasStatus: Recruiting, Estimated PCD: 2024-12-31